Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones

Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi Stocks to buy in 2026. On January 27, Tempus AI, Inc. (NASDAQ:TEM) confirmed that its Immune Profile Score Test accurately predicts patient outcomes for immune checkpoint inhibitor therapy, compared with conventional biomarkers. Consequently, it continues to demonstrate superior predictive accuracy, with a hazard ratio of 0.45.

On January 21, Tempus AI introduced Paige Predict, an AI-powered digital pathology tool designed to analyze H&E whole slide images and predict 123 biomarkers across 16 cancer types, helping clinicians decide which confirmatory tests to run when tissue samples are limited. Built following Tempus’s 2025 acquisition of Paige, the tool is based on a foundation model trained on data from more than 200,000 patients and validated across multiple datasets. Despite operating at a loss, Tempus reported a 61.7% gross margin and says Paige Predict supports its broader goal of advancing precision medicine by embedding actionable insights directly into clinical reports.

Earlier on January 11, Tempus AI, Inc. announced a record Total Contract Value exceeding $1.1 billion at the end of 2025.

The $1.1 billion milestone came on the company’s signing of data agreements with over 70 customers spanning large and midsize companies. Some of the big customers the company inked deals with include AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, and Novartis. In addition, the company achieved a net revenue retention of 126%, affirming the strengthening of relationships with existing customers.

“2025 was a record year for our Data and applications business – both from a revenue and TCV perspective,” said Jim Rogers, Chief Financial Officer at Tempus. “Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”

Tempus AI, Inc. (NASDAQ:TEM) is a technology company that applies artificial intelligence (AI) to precision medicine, primarily focusing on collecting and analyzing clinical and molecular data to help physicians personalize care.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.